{"id":19552,"date":"2026-09-16T09:58:50","date_gmt":"2026-09-16T09:58:50","guid":{"rendered":"https:\/\/www.simpleonlinepharmacy.co.uk\/health-advice\/?p=19552"},"modified":"2026-09-16T09:58:52","modified_gmt":"2026-09-16T09:58:52","slug":"foundayo-vs-wegovy-injection","status":"publish","type":"post","link":"https:\/\/www.simpleonlinepharmacy.co.uk\/health-advice\/weight-loss\/foundayo\/foundayo-vs-wegovy-injection\/","title":{"rendered":"Foundayo vs Wegovy Injection"},"content":{"rendered":"\n

What are the main differences between Foundayo and Wegovy injection?<\/h2>\n\n\n\n

Foundayo is a tablet you swallow once a day. The Wegovy injection is a pen device you inject under your skin once a week.<\/strong><\/p>\n\n\n\n

Foundayo (orforglipron) contains a non-peptide molecule. It comes as a tablet at any time of day, with or without food.<\/p>\n\n\n\n

Wegovy injection contains semaglutide, a peptide copy of a hormone your gut releases after you eat. Peptide medicines are poorly absorbed when swallowed, which is why the tablet version of Wegovy needs strict timing rules. Injection avoids the problem by delivering the medicine straight into the tissue under your skin.<\/p>\n\n\n\n

The two medicines also hold different UK licences beyond weight management. Foundayo is licensed to improve blood sugar control in type 2 diabetes. Wegovy injection is licensed to lower the risk of heart attack, stroke or death from heart disease in adults who already have heart disease.<\/p>\n\n\n\n

A separate Wegovy licence covers metabolic dysfunction-associated steatohepatitis, or MASH, a liver condition. It applies to adults with moderate to advanced scarring, but not cirrhosis.\u00a0<\/p>\n\n\n\n

Dose schedules differ in the number of steps and frequency. Reaching the top Foundayo strength takes roughly five months, compared with about four months to 2.4mg on the injection. The Wegovy injection also offers a higher dose above its usual maintenance strength. A 7.2mg injection dose is available for adults with a BMI of 30 or above.<\/p>\n\n\n\n

 <\/td>Foundayo (orforglipron)<\/strong><\/td>Wegovy injection (semaglutide)<\/strong><\/td><\/tr>
Form<\/strong><\/td>Tablet GLP-1, swallowed whole<\/td>Injectable GLP-1, given under the skin<\/td><\/tr>
How often<\/strong><\/td>Once a day<\/td>Once a week<\/td><\/tr>
Type of molecule<\/strong><\/td>Non-peptide small molecule<\/td>Peptide<\/td><\/tr>
Starting dose<\/strong><\/td>0.8mg<\/td>0.25mg<\/td><\/tr>
Highest licensed dose<\/strong><\/td>17.2mg<\/a><\/td>2.4mg<\/a>, or a higher dose of 7.2mg<\/a> where eligible.<\/td><\/tr>
Steps to the top dose<\/strong><\/td>Six strengths, 30 days minimum at each<\/td>Four steps over 16 weeks. A further step to 7.2mg in obesity only.<\/td><\/tr>
Food and timing rules<\/strong><\/td>None<\/td>None<\/td><\/tr>
Also licensed for<\/strong><\/td>Type 2 diabetes<\/td>Heart risk reduction, MASH with liver scarring<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

How do the results compare?<\/h2>\n\n\n\n

Wegovy injection produced a greater average weight loss than Foundayo in each of their trials. Nobody has tested the two against each other in one trial.<\/strong> ATTAIN-1 and STEP 1 were separate clinical trials, run years apart in different groups of people.<\/p>\n\n\n\n

Both trials paired the medicine with dietary changes and increased physical activity. STEP 1 also gave its participants counselling every four weeks. The table figures show what the medicines added on top of that support.<\/p>\n\n\n\n

At the highest licensed dose<\/strong><\/td>Foundayo 17.2mg (<\/strong>ATTAIN-1<\/strong><\/a>, 72 weeks)<\/strong><\/td>Wegovy injection 2.4mg (<\/strong>STEP 1<\/strong><\/a>, 68 weeks)<\/strong><\/td><\/tr>
Average change in body weight<\/strong><\/td>-11.2%<\/td>-14.9%<\/td><\/tr>
Placebo group<\/strong><\/td>-2.1%<\/td>-2.4%<\/td><\/tr>
Lost 10% or more<\/strong><\/td>54.6%<\/td>69.1%<\/td><\/tr>
Lost 15% or more<\/strong><\/td>36.0%<\/td>50.5%<\/td><\/tr>
Lost 20% or more<\/strong><\/td>18.4%<\/td>32.0%<\/td><\/tr>
Average starting weight<\/strong><\/td>103.1kg<\/td>105.4kg<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The average weight change includes everyone who started. The threshold figures count only people measured at the end. <\/em><\/p>\n\n\n\n

Both figures come from the highest licensed dose in each trial, measured against placebo, an inactive treatment. People in the placebo group lost much less weight in each trial, at around 2%.<\/p>\n\n\n\n

More than half the people on the top Foundayo dose lost at least a tenth of their body weight, and nearly one in five lost a fifth or more. Choosing the tablet does not mean giving up on meaningful weight loss. <\/p>\n\n\n\n

Long-term results depend on staying on treatment. STEP 1 followed a group for a year after they stopped semaglutide, and weight climbed back. Participants finished about 5.6% below their original weight. Foundayo has no equivalent withdrawal study yet.<\/p>\n\n\n\n

Some people never reach the top dose at all. Side effects ended treatment for one in ten people on the highest Foundayo dose in ATTAIN-1. Anyone who settles at a lower dose should expect less weight loss than the trial average. <\/p>\n\n\n\n

Which has fewer side effects?<\/h2>\n\n\n\n

Stomach side effects are common with both medicines, but the pattern is not identical.<\/strong> Only Wegovy injection carries a chance of a reaction at the injection site.<\/p>\n\n\n\n

Most of these effects were mild or moderate in both trials, and they cluster as the dose is going up. For most people, they settle as the body adjusts. <\/p>\n\n\n\n

 <\/td>Foundayo 17.2mg<\/strong><\/td>Placebo<\/strong><\/td>Wegovy injection 2.4mg<\/strong><\/td>Placebo<\/strong><\/td><\/tr>
Nausea<\/strong><\/td>33.7%<\/td>10.4%<\/td>44.2%<\/td>17.4%<\/td><\/tr>
Vomiting<\/strong><\/td>24.0%<\/td>3.5%<\/td>24.8%<\/td>6.6%<\/td><\/tr>
Diarrhoea<\/strong><\/td>23.1%<\/td>9.6%<\/td>31.5%<\/td>15.9%<\/td><\/tr>
Constipation<\/strong><\/td>25.4%<\/td>9.3%<\/td>23.4%<\/td>9.5%<\/td><\/tr>
Indigestion<\/strong><\/td>14.1%<\/td>5.0%<\/td>10.3%<\/td>3.5%<\/td><\/tr>
Stopped treatment because of stomach effects<\/strong><\/td>7.0%<\/td>0.4%<\/td>4.5%<\/td>0.8%<\/td><\/tr>
Injection site reactions<\/strong><\/td>Does not apply<\/td>Does not apply<\/td>5.0%<\/td>6.7%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Foundayo figures come from<\/em> ATTAIN-1 at the 36mg capsule dose<\/a> , which has the same effect as the 17.2mg tablet. <\/em> Wegovy injection figures come from STEP 1<\/a>. Each placebo column belongs to its own trial.<\/em><\/p>\n\n\n\n

Side effects often ease with a slower move up through the doses, and with changes to when and what you eat. Talk to us before you stop or reduce a dose.<\/p>\n\n\n\n

Do Foundayo and Wegovy injection interact with other medicines?<\/h3>\n\n\n\n

Foundayo comes with more drug interactions to check than Wegovy injection.<\/strong> Your liver breaks Foundayo down using an enzyme that many other medicines also use. <\/p>\n\n\n\n

Some medicines, such as clarithromycin and itraconazole, can increase Foundayo levels. Your maximum Foundayo dose drops to 9mg while you take them. Rifampicin, phenytoin and St John’s wort do the opposite and can stop Foundayo from working. Anyone taking simvastatin needs a lower statin dose while on Foundayo, so speak to your GP first. <\/p>\n\n\n\n

Foundayo may also reduce how well oral hormonal contraceptives work. Add a barrier method, or switch to a non-oral contraceptive, for 30 days after starting. Do the same for 30 days after every dose increase.<\/p>\n\n\n\n

Wegovy injection has far less to check. It slows your stomach, and your body may take up other tablets more slowly. No dose caps apply, and it doesn’t include contraceptive advice.<\/p>\n\n\n\n

Whichever GLP-1 treatment you choose, tell us about all the medicines you take before you start. Include prescription and over-the-counter medicines plus any vitamins, supplements and herbal treatments. <\/p>\n\n\n\n

Which is more convenient?<\/h2>\n\n\n\n

Foundayo means a daily pill with no rules attached, while Wegovy injection is given once a week.<\/strong> Take Foundayo at any time, with or without food or water, and swallow it whole. <\/p>\n\n\n\n

The Wegovy injection is given into your abdomen, thigh or upper arm, at any time of day and with or without meals. You can move your injection day, as long as at least three days sit between doses.<\/p>\n\n\n\n

With Foundayo, take a missed tablet as soon as you remember, and do not take two in one day. With the Wegovy injection, you have five days to catch up, then skip the dose and carry on.<\/p>\n\n\n\n

You need to keep the Wegovy injection in the fridge between 2\u00b0C and 8\u00b0C before first use. Once you start a pen, you have six weeks to finish it and can store it in the fridge or below 30\u00b0C. Used pens go into a sharps bin rather than your household waste. Foundayo leaves you nothing to dispose of, and the tablets need no fridge. <\/p>\n\n\n\n

Is a daily pill always easier than weekly injections?<\/h3>\n\n\n\n

Not every GLP-1 in pill form is as simple as Foundayo.<\/strong> The UK licence for oral Wegovy<\/a> asks for an empty stomach, after an eight-hour fast and 120ml of water at most. You then wait 30 minutes before eating. Absorption varies more day-to-day than with the injectable version.<\/p>\n\n\n\n

Oral semaglutide vs injection is therefore not the same choice as Foundayo vs injection. Weekly injections mean one dose to remember rather than seven. A daily dose suits anyone who would rather avoid needles entirely.<\/p>\n\n\n\n

Which one fits your situation?<\/h2>\n\n\n\n

The right choice turns on which difference matters most to you, and the trial figures are only one of them.<\/strong><\/p>\n\n\n\n